Literature DB >> 11948141

Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.

Jonathan I Izawa1, Paul Sweeney, Paul Perrotte, Daniel Kedar, Zhongyun Dong, Joel W Slaton, Takashi Karashima, Keji Inoue, William F Benedict, Colin P N Dinney.   

Abstract

We determined whether the IFN-beta gene could suppress angiogenesis, tumor growth, and metastasis of human bladder transitional cell carcinoma. The highly tumorigenic and metastatic 253J B-V(R) human bladder transitional cell carcinoma (TCC) cell line (resistant to the antiproliferative effects of IFN-beta) was infected in vitro with adenoviral beta-galactosidase (Ad-LacZ), murine adenoviral IFN-beta (Ad-mIFN-beta), or human adenoviral IFN-beta (Ad-hIFN-beta) and implanted into the bladders of athymic nude mice. Ad-mIFN-beta and Ad-hIFN-beta were used because of the species specificity of IFN-beta. The transient production of mIFN-beta and hIFN-beta from the infected 253JB-V(R) tumor cells significantly inhibited tumorigenicity and spontaneous lymph node metastasis. Subsequently, the 253J B-V(R) cells were implanted into the subcutis of athymic nude mice, and established tumors were treated by direct intratumoral injection with Ad-mIFN-beta, Ad-hIFN-beta, Ad-LacZ, or PBS. By in situ hybridization (ISH) and immunohistochemical analysis (IHC), expression of hIFN-beta and mIFN-beta mRNA and protein within the tumors was demonstrated after Ad-hIFN-beta and Ad-mIFN-beta gene therapy, respectively. The therapy also induced necrosis in both the Ad-mIFN-beta- and Ad-hIFN-beta-treated tumors. IHC revealed decreased tumor cell proliferation and the sequestration of activated macrophages within the tumors after Ad-mIFN-beta therapy. In addition, the expression of the proangiogenic factors bFGF, and MMP-9 protein (by IHC) was significantly down-regulated by Ad-hIFN-beta gene therapy. Double-immunofluorescent IHC for terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) and CD-31 demonstrated tumor and endothelial cell apoptosis in those tumors treated with Ad-hIFN-beta gene therapy. Tumor-induced angiogenesis, as determined by the microvessel density, was decreased in tumors treated with both Ad-mIFN-beta and Ad-hIFN-beta. These data suggest that the inhibition of tumorigenicity and the metastasis of the 253J B-V(R) cells after infection with Ad-IFN-beta is caused by the inhibition of angiogenesis and the activation of host effector cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948141

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

Review 1.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.

Authors:  David J McConkey; Woonyoung Choi; Lauren Marquis; Frances Martin; Michael B Williams; Jay Shah; Robert Svatek; Aditi Das; Liana Adam; Ashish Kamat; Arlene Siefker-Radtke; Colin Dinney
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

2.  Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma.

Authors:  Peng-Yuan Zhuang; Ju-Bo Zhang; Wei Zhang; Xiao-Dong Zhu; Ying Liang; Hua-Xiang Xu; Yu-Quan Xiong; Ling-Qun Kong; Lu Wang; Wei-Zhong Wu; Zhao-You Tang; Lun-Xiu Qin; Hui-Chuan Sun
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

3.  Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma.

Authors:  Shuzhe Yang; Xiaohou Wu; Chunli Luo; Cuicui Pan; Jun Pu
Journal:  World J Urol       Date:  2010-07-01       Impact factor: 4.226

Review 4.  The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.

Authors:  Jonathan J Duplisea; Sharada Mokkapati; Devin Plote; Kimberly S Schluns; David J McConkey; Seppo Yla-Herttuala; Nigel R Parker; Colin P Dinney
Journal:  World J Urol       Date:  2018-11-11       Impact factor: 4.226

5.  Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Authors:  Neal D Shore; Stephen A Boorjian; Daniel J Canter; Kenneth Ogan; Lawrence I Karsh; Tracy M Downs; Leonard G Gomella; Ashish M Kamat; Yair Lotan; Robert S Svatek; Trinity J Bivalacqua; Robert L Grubb; Tracey L Krupski; Seth P Lerner; Michael E Woods; Brant A Inman; Matthew I Milowsky; Alan Boyd; F Peter Treasure; Gillian Gregory; David G Sawutz; Seppo Yla-Herttuala; Nigel R Parker; Colin P N Dinney
Journal:  J Clin Oncol       Date:  2017-08-23       Impact factor: 44.544

6.  The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.

Authors:  Khalid A Mohamedali; Daniel Kedar; Paul Sweeney; Ashish Kamat; Darren W Davis; Beryl Y Eve; Samuel Huang; Philip E Thorpe; Colin P Dinney; Michael G Rosenblum
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

7.  Angiostatin inhibits pancreatic cancer cell proliferation and growth in nude mice.

Authors:  Ding-Zhong Yang; Jing He; Ji-Cheng Zhang; Zhuo-Ren Wang
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

8.  Significance of apoptosis in metastasizing testis tumors.

Authors:  M Abend; M Port; H U Schmelz; K Kraft; C Sparwasser
Journal:  Urol Res       Date:  2003-10-25

9.  Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response.

Authors:  Randall S MacGill; Thomas A Davis; Jennifer Macko; Helena J Mauceri; Ralph R Weichselbaum; C Richter King
Journal:  Clin Exp Metastasis       Date:  2007-07-25       Impact factor: 5.150

10.  Preventing growth of brain tumors by creating a zone of resistance.

Authors:  Casey A Maguire; Dimphna H Meijer; Stanley G LeRoy; Laryssa A Tierney; Marike L D Broekman; Fabricio F Costa; Xandra O Breakefield; Anat Stemmer-Rachamimov; Miguel Sena-Esteves
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.